

Global Meningococcal Disease Vaccine Market Growth 2023-2029

<https://marketpublishers.com/r/G7D9D14BCDCAEN.html>

Date: March 2023

Pages: 106

Price: US\$ 3,660.00 (Single User License)

ID: G7D9D14BCDCAEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Meningococcal Disease Vaccine market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Meningococcal Disease Vaccine is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Meningococcal Disease Vaccine is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Meningococcal Disease Vaccine is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Meningococcal Disease Vaccine players cover AstraZeneca, Johnson & Johnson, Mylan N.V, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Sanofi and Merck & Co., Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to

combat the bacteria and develop an immune response to prevent infection.

LPI (LP Information)' newest research report, the “Meningococcal Disease Vaccine Industry Forecast” looks at past sales and reviews total world Meningococcal Disease Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Meningococcal Disease Vaccine sales for 2023 through 2029. With Meningococcal Disease Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Meningococcal Disease Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Meningococcal Disease Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Meningococcal Disease Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Meningococcal Disease Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Meningococcal Disease Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Meningococcal Disease Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Meningococcal Disease Vaccine market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Polysaccharide

Conjugate

Combination

Segmentation by application

Infant

Child

Adult

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

AstraZeneca

Johnson & Johnson

Mylan N.V

Teva Pharmaceutical Industries Ltd

Pfizer Inc

GlaxoSmithKline plc

Novartis AG

Sanofi

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd

Baxter

BIO-MED

Bio-Manguinhos

Walvax Biotechnology Co., Ltd

Key Questions Addressed in this Report

What is the 10-year outlook for the global Meningococcal Disease Vaccine market?

What factors are driving Meningococcal Disease Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Meningococcal Disease Vaccine market opportunities vary by end market size?

How does Meningococcal Disease Vaccine break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Meningococcal Disease Vaccine Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Meningococcal Disease Vaccine by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Meningococcal Disease Vaccine by Country/Region, 2018, 2022 & 2029
- 2.2 Meningococcal Disease Vaccine Segment by Type
 - 2.2.1 Polysaccharide
 - 2.2.2 Conjugate
 - 2.2.3 Combination
- 2.3 Meningococcal Disease Vaccine Sales by Type
 - 2.3.1 Global Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Meningococcal Disease Vaccine Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Meningococcal Disease Vaccine Sale Price by Type (2018-2023)
- 2.4 Meningococcal Disease Vaccine Segment by Application
 - 2.4.1 Infant
 - 2.4.2 Child
 - 2.4.3 Adult
- 2.5 Meningococcal Disease Vaccine Sales by Application
 - 2.5.1 Global Meningococcal Disease Vaccine Sale Market Share by Application (2018-2023)
 - 2.5.2 Global Meningococcal Disease Vaccine Revenue and Market Share by

Application (2018-2023)

2.5.3 Global Meningococcal Disease Vaccine Sale Price by Application (2018-2023)

3 GLOBAL MENINGOCOCCAL DISEASE VACCINE BY COMPANY

3.1 Global Meningococcal Disease Vaccine Breakdown Data by Company

3.1.1 Global Meningococcal Disease Vaccine Annual Sales by Company (2018-2023)

3.1.2 Global Meningococcal Disease Vaccine Sales Market Share by Company (2018-2023)

3.2 Global Meningococcal Disease Vaccine Annual Revenue by Company (2018-2023)

3.2.1 Global Meningococcal Disease Vaccine Revenue by Company (2018-2023)

3.2.2 Global Meningococcal Disease Vaccine Revenue Market Share by Company (2018-2023)

3.3 Global Meningococcal Disease Vaccine Sale Price by Company

3.4 Key Manufacturers Meningococcal Disease Vaccine Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Meningococcal Disease Vaccine Product Location Distribution

3.4.2 Players Meningococcal Disease Vaccine Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR MENINGOCOCCAL DISEASE VACCINE BY GEOGRAPHIC REGION

4.1 World Historic Meningococcal Disease Vaccine Market Size by Geographic Region (2018-2023)

4.1.1 Global Meningococcal Disease Vaccine Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Meningococcal Disease Vaccine Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Meningococcal Disease Vaccine Market Size by Country/Region (2018-2023)

4.2.1 Global Meningococcal Disease Vaccine Annual Sales by Country/Region (2018-2023)

4.2.2 Global Meningococcal Disease Vaccine Annual Revenue by Country/Region

(2018-2023)

4.3 Americas Meningococcal Disease Vaccine Sales Growth

4.4 APAC Meningococcal Disease Vaccine Sales Growth

4.5 Europe Meningococcal Disease Vaccine Sales Growth

4.6 Middle East & Africa Meningococcal Disease Vaccine Sales Growth

5 AMERICAS

5.1 Americas Meningococcal Disease Vaccine Sales by Country

5.1.1 Americas Meningococcal Disease Vaccine Sales by Country (2018-2023)

5.1.2 Americas Meningococcal Disease Vaccine Revenue by Country (2018-2023)

5.2 Americas Meningococcal Disease Vaccine Sales by Type

5.3 Americas Meningococcal Disease Vaccine Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Meningococcal Disease Vaccine Sales by Region

6.1.1 APAC Meningococcal Disease Vaccine Sales by Region (2018-2023)

6.1.2 APAC Meningococcal Disease Vaccine Revenue by Region (2018-2023)

6.2 APAC Meningococcal Disease Vaccine Sales by Type

6.3 APAC Meningococcal Disease Vaccine Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Meningococcal Disease Vaccine by Country

7.1.1 Europe Meningococcal Disease Vaccine Sales by Country (2018-2023)

7.1.2 Europe Meningococcal Disease Vaccine Revenue by Country (2018-2023)

7.2 Europe Meningococcal Disease Vaccine Sales by Type

7.3 Europe Meningococcal Disease Vaccine Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Meningococcal Disease Vaccine by Country

8.1.1 Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2018-2023)

8.1.2 Middle East & Africa Meningococcal Disease Vaccine Revenue by Country (2018-2023)

8.2 Middle East & Africa Meningococcal Disease Vaccine Sales by Type

8.3 Middle East & Africa Meningococcal Disease Vaccine Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Meningococcal Disease Vaccine

10.3 Manufacturing Process Analysis of Meningococcal Disease Vaccine

10.4 Industry Chain Structure of Meningococcal Disease Vaccine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

- 11.1.2 Indirect Channels
- 11.2 Meningococcal Disease Vaccine Distributors
- 11.3 Meningococcal Disease Vaccine Customer

12 WORLD FORECAST REVIEW FOR MENINGOCOCCAL DISEASE VACCINE BY GEOGRAPHIC REGION

- 12.1 Global Meningococcal Disease Vaccine Market Size Forecast by Region
 - 12.1.1 Global Meningococcal Disease Vaccine Forecast by Region (2024-2029)
 - 12.1.2 Global Meningococcal Disease Vaccine Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Meningococcal Disease Vaccine Forecast by Type
- 12.7 Global Meningococcal Disease Vaccine Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 AstraZeneca
 - 13.1.1 AstraZeneca Company Information
 - 13.1.2 AstraZeneca Meningococcal Disease Vaccine Product Portfolios and Specifications
 - 13.1.3 AstraZeneca Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.1.4 AstraZeneca Main Business Overview
 - 13.1.5 AstraZeneca Latest Developments
- 13.2 Johnson & Johnson
 - 13.2.1 Johnson & Johnson Company Information
 - 13.2.2 Johnson & Johnson Meningococcal Disease Vaccine Product Portfolios and Specifications
 - 13.2.3 Johnson & Johnson Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.2.4 Johnson & Johnson Main Business Overview
 - 13.2.5 Johnson & Johnson Latest Developments
- 13.3 Mylan N.V.
 - 13.3.1 Mylan N.V. Company Information
 - 13.3.2 Mylan N.V. Meningococcal Disease Vaccine Product Portfolios and

Specifications

13.3.3 Mylan N.V Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Mylan N.V Main Business Overview

13.3.5 Mylan N.V Latest Developments

13.4 Teva Pharmaceutical Industries Ltd

13.4.1 Teva Pharmaceutical Industries Ltd Company Information

13.4.2 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications

13.4.3 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Teva Pharmaceutical Industries Ltd Main Business Overview

13.4.5 Teva Pharmaceutical Industries Ltd Latest Developments

13.5 Pfizer Inc

13.5.1 Pfizer Inc Company Information

13.5.2 Pfizer Inc Meningococcal Disease Vaccine Product Portfolios and

Specifications

13.5.3 Pfizer Inc Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Pfizer Inc Main Business Overview

13.5.5 Pfizer Inc Latest Developments

13.6 GlaxoSmithKline plc

13.6.1 GlaxoSmithKline plc Company Information

13.6.2 GlaxoSmithKline plc Meningococcal Disease Vaccine Product Portfolios and Specifications

13.6.3 GlaxoSmithKline plc Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 GlaxoSmithKline plc Main Business Overview

13.6.5 GlaxoSmithKline plc Latest Developments

13.7 Novartis AG

13.7.1 Novartis AG Company Information

13.7.2 Novartis AG Meningococcal Disease Vaccine Product Portfolios and

Specifications

13.7.3 Novartis AG Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Novartis AG Main Business Overview

13.7.5 Novartis AG Latest Developments

13.8 Sanofi

13.8.1 Sanofi Company Information

- 13.8.2 Sanofi Meningococcal Disease Vaccine Product Portfolios and Specifications
- 13.8.3 Sanofi Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.8.4 Sanofi Main Business Overview
- 13.8.5 Sanofi Latest Developments
- 13.9 Merck & Co., Inc.
 - 13.9.1 Merck & Co., Inc. Company Information
 - 13.9.2 Merck & Co., Inc. Meningococcal Disease Vaccine Product Portfolios and Specifications
 - 13.9.3 Merck & Co., Inc. Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.9.4 Merck & Co., Inc. Main Business Overview
 - 13.9.5 Merck & Co., Inc. Latest Developments
- 13.10 F. Hoffmann-La Roche Ltd
 - 13.10.1 F. Hoffmann-La Roche Ltd Company Information
 - 13.10.2 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
 - 13.10.3 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.10.4 F. Hoffmann-La Roche Ltd Main Business Overview
 - 13.10.5 F. Hoffmann-La Roche Ltd Latest Developments
- 13.11 Baxter
 - 13.11.1 Baxter Company Information
 - 13.11.2 Baxter Meningococcal Disease Vaccine Product Portfolios and Specifications
 - 13.11.3 Baxter Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.11.4 Baxter Main Business Overview
 - 13.11.5 Baxter Latest Developments
- 13.12 BIO-MED
 - 13.12.1 BIO-MED Company Information
 - 13.12.2 BIO-MED Meningococcal Disease Vaccine Product Portfolios and Specifications
 - 13.12.3 BIO-MED Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.12.4 BIO-MED Main Business Overview
 - 13.12.5 BIO-MED Latest Developments
- 13.13 Bio-Manguinhos
 - 13.13.1 Bio-Manguinhos Company Information
 - 13.13.2 Bio-Manguinhos Meningococcal Disease Vaccine Product Portfolios and

Specifications

13.13.3 Bio-Manguinhos Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)

13.13.4 Bio-Manguinhos Main Business Overview

13.13.5 Bio-Manguinhos Latest Developments

13.14 Walvax Biotechnology Co., Ltd

13.14.1 Walvax Biotechnology Co., Ltd Company Information

13.14.2 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product

Portfolios and Specifications

13.14.3 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)

13.14.4 Walvax Biotechnology Co., Ltd Main Business Overview

13.14.5 Walvax Biotechnology Co., Ltd Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Meningococcal Disease Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. Meningococcal Disease Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of Polysaccharide
- Table 4. Major Players of Conjugate
- Table 5. Major Players of Combination
- Table 6. Global Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
- Table 7. Global Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
- Table 8. Global Meningococcal Disease Vaccine Revenue by Type (2018-2023) & (\$ million)
- Table 9. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2018-2023)
- Table 10. Global Meningococcal Disease Vaccine Sale Price by Type (2018-2023) & (US\$/Unit)
- Table 11. Global Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
- Table 12. Global Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)
- Table 13. Global Meningococcal Disease Vaccine Revenue by Application (2018-2023)
- Table 14. Global Meningococcal Disease Vaccine Revenue Market Share by Application (2018-2023)
- Table 15. Global Meningococcal Disease Vaccine Sale Price by Application (2018-2023) & (US\$/Unit)
- Table 16. Global Meningococcal Disease Vaccine Sales by Company (2018-2023) & (K Units)
- Table 17. Global Meningococcal Disease Vaccine Sales Market Share by Company (2018-2023)
- Table 18. Global Meningococcal Disease Vaccine Revenue by Company (2018-2023) (\$ Millions)
- Table 19. Global Meningococcal Disease Vaccine Revenue Market Share by Company (2018-2023)
- Table 20. Global Meningococcal Disease Vaccine Sale Price by Company (2018-2023) & (US\$/Unit)

- Table 21. Key Manufacturers Meningococcal Disease Vaccine Producing Area Distribution and Sales Area
- Table 22. Players Meningococcal Disease Vaccine Products Offered
- Table 23. Meningococcal Disease Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- Table 24. New Products and Potential Entrants
- Table 25. Mergers & Acquisitions, Expansion
- Table 26. Global Meningococcal Disease Vaccine Sales by Geographic Region (2018-2023) & (K Units)
- Table 27. Global Meningococcal Disease Vaccine Sales Market Share Geographic Region (2018-2023)
- Table 28. Global Meningococcal Disease Vaccine Revenue by Geographic Region (2018-2023) & (\$ millions)
- Table 29. Global Meningococcal Disease Vaccine Revenue Market Share by Geographic Region (2018-2023)
- Table 30. Global Meningococcal Disease Vaccine Sales by Country/Region (2018-2023) & (K Units)
- Table 31. Global Meningococcal Disease Vaccine Sales Market Share by Country/Region (2018-2023)
- Table 32. Global Meningococcal Disease Vaccine Revenue by Country/Region (2018-2023) & (\$ millions)
- Table 33. Global Meningococcal Disease Vaccine Revenue Market Share by Country/Region (2018-2023)
- Table 34. Americas Meningococcal Disease Vaccine Sales by Country (2018-2023) & (K Units)
- Table 35. Americas Meningococcal Disease Vaccine Sales Market Share by Country (2018-2023)
- Table 36. Americas Meningococcal Disease Vaccine Revenue by Country (2018-2023) & (\$ Millions)
- Table 37. Americas Meningococcal Disease Vaccine Revenue Market Share by Country (2018-2023)
- Table 38. Americas Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
- Table 39. Americas Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
- Table 40. APAC Meningococcal Disease Vaccine Sales by Region (2018-2023) & (K Units)
- Table 41. APAC Meningococcal Disease Vaccine Sales Market Share by Region (2018-2023)

Table 42. APAC Meningococcal Disease Vaccine Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC Meningococcal Disease Vaccine Revenue Market Share by Region (2018-2023)

Table 44. APAC Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)

Table 45. APAC Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)

Table 46. Europe Meningococcal Disease Vaccine Sales by Country (2018-2023) & (K Units)

Table 47. Europe Meningococcal Disease Vaccine Sales Market Share by Country (2018-2023)

Table 48. Europe Meningococcal Disease Vaccine Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe Meningococcal Disease Vaccine Revenue Market Share by Country (2018-2023)

Table 50. Europe Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)

Table 51. Europe Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)

Table 52. Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2018-2023) & (K Units)

Table 53. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Country (2018-2023)

Table 54. Middle East & Africa Meningococcal Disease Vaccine Revenue by Country (2018-2023) & (\$ Millions)

Table 55. Middle East & Africa Meningococcal Disease Vaccine Revenue Market Share by Country (2018-2023)

Table 56. Middle East & Africa Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)

Table 57. Middle East & Africa Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)

Table 58. Key Market Drivers & Growth Opportunities of Meningococcal Disease Vaccine

Table 59. Key Market Challenges & Risks of Meningococcal Disease Vaccine

Table 60. Key Industry Trends of Meningococcal Disease Vaccine

Table 61. Meningococcal Disease Vaccine Raw Material

Table 62. Key Suppliers of Raw Materials

Table 63. Meningococcal Disease Vaccine Distributors List

Table 64. Meningococcal Disease Vaccine Customer List

Table 65. Global Meningococcal Disease Vaccine Sales Forecast by Region (2024-2029) & (K Units)

Table 66. Global Meningococcal Disease Vaccine Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 67. Americas Meningococcal Disease Vaccine Sales Forecast by Country (2024-2029) & (K Units)

Table 68. Americas Meningococcal Disease Vaccine Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 69. APAC Meningococcal Disease Vaccine Sales Forecast by Region (2024-2029) & (K Units)

Table 70. APAC Meningococcal Disease Vaccine Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 71. Europe Meningococcal Disease Vaccine Sales Forecast by Country (2024-2029) & (K Units)

Table 72. Europe Meningococcal Disease Vaccine Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 73. Middle East & Africa Meningococcal Disease Vaccine Sales Forecast by Country (2024-2029) & (K Units)

Table 74. Middle East & Africa Meningococcal Disease Vaccine Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 75. Global Meningococcal Disease Vaccine Sales Forecast by Type (2024-2029) & (K Units)

Table 76. Global Meningococcal Disease Vaccine Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 77. Global Meningococcal Disease Vaccine Sales Forecast by Application (2024-2029) & (K Units)

Table 78. Global Meningococcal Disease Vaccine Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 79. AstraZeneca Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 80. AstraZeneca Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 81. AstraZeneca Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 82. AstraZeneca Main Business

Table 83. AstraZeneca Latest Developments

Table 84. Johnson & Johnson Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 85. Johnson & Johnson Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 86. Johnson & Johnson Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 87. Johnson & Johnson Main Business

Table 88. Johnson & Johnson Latest Developments

Table 89. Mylan N.V Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 90. Mylan N.V Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 91. Mylan N.V Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 92. Mylan N.V Main Business

Table 93. Mylan N.V Latest Developments

Table 94. Teva Pharmaceutical Industries Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 95. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 96. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 97. Teva Pharmaceutical Industries Ltd Main Business

Table 98. Teva Pharmaceutical Industries Ltd Latest Developments

Table 99. Pfizer Inc Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 100. Pfizer Inc Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 101. Pfizer Inc Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 102. Pfizer Inc Main Business

Table 103. Pfizer Inc Latest Developments

Table 104. GlaxoSmithKline plc Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 105. GlaxoSmithKline plc Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 106. GlaxoSmithKline plc Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 107. GlaxoSmithKline plc Main Business

Table 108. GlaxoSmithKline plc Latest Developments

Table 109. Novartis AG Basic Information, Meningococcal Disease Vaccine

Manufacturing Base, Sales Area and Its Competitors

Table 110. Novartis AG Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 111. Novartis AG Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 112. Novartis AG Main Business

Table 113. Novartis AG Latest Developments

Table 114. Sanofi Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 115. Sanofi Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 116. Sanofi Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 117. Sanofi Main Business

Table 118. Sanofi Latest Developments

Table 119. Merck & Co., Inc. Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 120. Merck & Co., Inc. Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 121. Merck & Co., Inc. Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 122. Merck & Co., Inc. Main Business

Table 123. Merck & Co., Inc. Latest Developments

Table 124. F. Hoffmann-La Roche Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 125. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 126. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 127. F. Hoffmann-La Roche Ltd Main Business

Table 128. F. Hoffmann-La Roche Ltd Latest Developments

Table 129. Baxter Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 130. Baxter Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 131. Baxter Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 132. Baxter Main Business

Table 133. Baxter Latest Developments

Table 134. BIO-MED Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 135. BIO-MED Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 136. BIO-MED Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 137. BIO-MED Main Business

Table 138. BIO-MED Latest Developments

Table 139. Bio-Manguinhos Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 140. Bio-Manguinhos Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 141. Bio-Manguinhos Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 142. Bio-Manguinhos Main Business

Table 143. Bio-Manguinhos Latest Developments

Table 144. Walvax Biotechnology Co., Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 145. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications

Table 146. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 147. Walvax Biotechnology Co., Ltd Main Business

Table 148. Walvax Biotechnology Co., Ltd Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Meningococcal Disease Vaccine
- Figure 2. Meningococcal Disease Vaccine Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Meningococcal Disease Vaccine Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Meningococcal Disease Vaccine Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Meningococcal Disease Vaccine Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Polysaccharide
- Figure 10. Product Picture of Conjugate
- Figure 11. Product Picture of Combination
- Figure 12. Global Meningococcal Disease Vaccine Sales Market Share by Type in 2022
- Figure 13. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2018-2023)
- Figure 14. Meningococcal Disease Vaccine Consumed in Infant
- Figure 15. Global Meningococcal Disease Vaccine Market: Infant (2018-2023) & (K Units)
- Figure 16. Meningococcal Disease Vaccine Consumed in Child
- Figure 17. Global Meningococcal Disease Vaccine Market: Child (2018-2023) & (K Units)
- Figure 18. Meningococcal Disease Vaccine Consumed in Adult
- Figure 19. Global Meningococcal Disease Vaccine Market: Adult (2018-2023) & (K Units)
- Figure 20. Global Meningococcal Disease Vaccine Sales Market Share by Application (2022)
- Figure 21. Global Meningococcal Disease Vaccine Revenue Market Share by Application in 2022
- Figure 22. Meningococcal Disease Vaccine Sales Market by Company in 2022 (K Units)
- Figure 23. Global Meningococcal Disease Vaccine Sales Market Share by Company in 2022
- Figure 24. Meningococcal Disease Vaccine Revenue Market by Company in 2022 (\$ Million)

Figure 25. Global Meningococcal Disease Vaccine Revenue Market Share by Company in 2022

Figure 26. Global Meningococcal Disease Vaccine Sales Market Share by Geographic Region (2018-2023)

Figure 27. Global Meningococcal Disease Vaccine Revenue Market Share by Geographic Region in 2022

Figure 28. Americas Meningococcal Disease Vaccine Sales 2018-2023 (K Units)

Figure 29. Americas Meningococcal Disease Vaccine Revenue 2018-2023 (\$ Millions)

Figure 30. APAC Meningococcal Disease Vaccine Sales 2018-2023 (K Units)

Figure 31. APAC Meningococcal Disease Vaccine Revenue 2018-2023 (\$ Millions)

Figure 32. Europe Meningococcal Disease Vaccine Sales 2018-2023 (K Units)

Figure 33. Europe Meningococcal Disease Vaccine Revenue 2018-2023 (\$ Millions)

Figure 34. Middle East & Africa Meningococcal Disease Vaccine Sales 2018-2023 (K Units)

Figure 35. Middle East & Africa Meningococcal Disease Vaccine Revenue 2018-2023 (\$ Millions)

Figure 36. Americas Meningococcal Disease Vaccine Sales Market Share by Country in 2022

Figure 37. Americas Meningococcal Disease Vaccine Revenue Market Share by Country in 2022

Figure 38. Americas Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)

Figure 39. Americas Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)

Figure 40. United States Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Canada Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Mexico Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 43. Brazil Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 44. APAC Meningococcal Disease Vaccine Sales Market Share by Region in 2022

Figure 45. APAC Meningococcal Disease Vaccine Revenue Market Share by Regions in 2022

Figure 46. APAC Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)

Figure 47. APAC Meningococcal Disease Vaccine Sales Market Share by Application

(2018-2023)

Figure 48. China Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 49. Japan Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 50. South Korea Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Southeast Asia Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 52. India Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Australia Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 54. China Taiwan Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Europe Meningococcal Disease Vaccine Sales Market Share by Country in 2022

Figure 56. Europe Meningococcal Disease Vaccine Revenue Market Share by Country in 2022

Figure 57. Europe Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)

Figure 58. Europe Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)

Figure 59. Germany Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 60. France Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 61. UK Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Italy Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Russia Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 64. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Country in 2022

Figure 65. Middle East & Africa Meningococcal Disease Vaccine Revenue Market Share by Country in 2022

Figure 66. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)

Figure 67. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by

Application (2018-2023)

Figure 68. Egypt Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 69. South Africa Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Israel Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Turkey Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 72. GCC Country Meningococcal Disease Vaccine Revenue Growth 2018-2023 (\$ Millions)

Figure 73. Manufacturing Cost Structure Analysis of Meningococcal Disease Vaccine in 2022

Figure 74. Manufacturing Process Analysis of Meningococcal Disease Vaccine

Figure 75. Industry Chain Structure of Meningococcal Disease Vaccine

Figure 76. Channels of Distribution

Figure 77. Global Meningococcal Disease Vaccine Sales Market Forecast by Region (2024-2029)

Figure 78. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Region (2024-2029)

Figure 79. Global Meningococcal Disease Vaccine Sales Market Share Forecast by Type (2024-2029)

Figure 80. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Type (2024-2029)

Figure 81. Global Meningococcal Disease Vaccine Sales Market Share Forecast by Application (2024-2029)

Figure 82. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Meningococcal Disease Vaccine Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G7D9D14BCDCAEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7D9D14BCDCAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970